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sults from a simulation designed to evaluate how well the
various methods perform under different circumstances.
Those who want to learn the techniques of multivariable
cost analysis and develop criteria for choosing the best
technique will benefit from this workshop. Participants
who would benefit include analysts of cost data and those
who want to increase their understanding of the literature
of economic evaluation.
CM.
USE OF UB·92S AND MEDICARE COST REPORTS
IN A LARGE, MULTI-CENTER RANDOMIZED
TRIAL: THE PURSUIT EXPERIENCE
Davidson-Ray LI, Buell HI, O'Neal BI, McElwee N2, Mark OBI
'Duke Clinical Research Institute, Durham, NC, USA; -Schering-
Plough Corp., Kenilworth, NJ, USA
The conversion of hospital bill charges using Uniform Bill
(UB)-92s and Medicare Ratios of Cost to Charges
(RCCs) to costs in economic analyses is one of the most
efficient, accurate and accessible ways of measuring re-
source consumption for US hospitalizations.
OBJECTIVES: We used the hospital bill charge to cost
conversion method in our analysis of over 3,000 patients
with 4,700 hospital bills in the recently completed PUR-
SUIT pharmacoeconomic substudy. Using the PURSUIT
trial experience as a model, this workshop will provide a
detailed explanation of the cost to charge conversion
methodology. We will begin with a detailed procedure
for incorporating this method of cost collection into a
clinical trial's overall protocol and case report form. We
will explain how to ensure collection of bills for all pa-
tient hospitalizations and procedures; how to interpret
the UB-92; how to extract charges from the UB-92 and
convert those charges into costs using each hospital's
Medicare Ratio of Cost to Charges. This workshop will
also explore mechanisms for ensuring successful compli-
ance across sites in large, randomized clinical trials in-
cluding inservice training for coordinators and common
obstacles to successful and complete collection. In addi-
tion, the workshop will explore the limitations and
strengths of this method compared with other cost collec-
tion methods. This workshop will be particularly useful
to project leaders, clinical trial coordinators, and database
managers interested in performing economic analyses as
part of larger clinical trials or as stand-alone endeavors.
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Most guidelines for economic analysis call for discount-
ing of health benefits. This major methodological point
has rapidly moved from debate to common practice. Yet,
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the powerful effect that discounting can have on an anal-
ysis means that it may become the dominant factor in a
therapeutic decision. These grave implications should
cause pharmacoeconomic analysts to take pause. This
workshop will examine the implications of discounting,
its rationale and counterpoints, in an effort to establish
whether discounting of benefits is justified or not. Topics
covered will be: The Basis for Discounting; The Logical
Implications of Discounting; and Discounting: A New
Approach. Pharmacoeconomics is a fast evolving field.
New thought should continually be put into refining its
methodology. Ultimately, the aim of this workshop is to
take time to rethink the various issues that surround dis-
counting of health benefits.
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This workshop offers a critical examination of the use of
patient self-reports in pharmacoeconomic evaluations.
This session is directed at individuals in pharmaceutical
firms, CROs, and consultancy companies who are re-
sponsible for the design and conduct of pharrnacoeco-
nomic evaluations. The workshop advances recent re-
search by concentrating on how the method of data
collection in prospective clinical economic evaluations
may influence study findings. Scant attention has been
paid to the fact that the high level of internal validity
found in prospective studies may be compromised by the
application of inappropriate methodologies to data col-
lection. Particular attention in this workshop is placed on
how validity may be affected by the elapsed time between
admission and self-reporting, salience of a treatment
event and perceived social desirability of a condition. As
part of this workshop we will highlight areas where esti-
mates based on patient self-reports lead to either reliable
or suspect values. In particular, we examine the areas of
hospitalization, outpatient consultations, medication use
and indirect costs. The impact that patient self-reports
have on cost-effectiveness ratios is also discussed. Attend-
ees at this workshop will gain an understanding of cur-
rent methodological shortcomings in this area and re-
searchers and readers of pharmacoeconomic studies will
gain the skills necessary to better design studies and eval-
uate the validity of, and potential for bias in cost-effec-
tiveness analyses.
